Ionis Pharmaceuticals' stake in the muscular disease treatment developer will be cut in an offering set to raise between $95m and $107m.
Dynacure, the France-based muscular disease treatment developer which counts pharmaceutical firm Ionis Pharmaceuticals as an investor, has set the range for an initial public offering that could raise up to $107m.
The company plans to offer 6.3 million American depository shares (ADSs), each representing one ordinary share, at a price range of $15 to $17 on the Nasdaq Global Market. The upper end of the range would imply a market valuation of approximately $334m.
Founded in 2016, Dynacure is developing…
